HB2197, titled the No 340B Savings for Transgender Care Act, would amend the federal Public Health Service Act to restrict how certain health care providers participating in the 340B drug discount program may use the savings they receive from purchasing covered outpatient drugs at reduced prices. Specifically, the bill would prohibit covered entities from using those savings to pay for sex reassignment surgeries or hormone treatments when those services are furnished for the purpose of gender alteration for a transgender individual.
The bill targets the 340B program’s financial benefits rather than directly banning the underlying medical services. By adding a new prohibition to the statute governing covered entities, it would create a federal restriction on the use of 340B-derived funds and define the covered services that cannot be supported with those savings. The measure was introduced in the House and referred to the Committee on Energy and Commerce, with no recorded committee hearing, amendment, or vote in the provided materials.
Impact
If enacted, the bill would amend Section 340B of the Public Health Service Act and narrow how hospitals, clinics, and other 340B covered entities may allocate program savings. It would not change the general legality of gender-affirming surgeries or hormone therapy, but it would bar the use of 340B discounts to subsidize those specific services, potentially affecting budgeting, service availability, and compliance practices for participating providers. The bill would also add a new statutory definition of prohibited services tied to transgender care.
Sentiment
The bill’s introduction suggests support among its Republican sponsors for limiting public health program resources from being used for gender-affirming care. Because no committee transcript or vote is provided, there is no recorded bipartisan debate or formal legislative outcome in the materials. The available context indicates the measure is politically charged and likely aligned with broader national disputes over transgender health care and the scope of the 340B program.
Contention
The main point of contention is whether federal drug-discount savings should be restricted from supporting gender-affirming care. Supporters appear to view the bill as preventing public or subsidized health resources from financing services they oppose, while opponents would likely argue that it singles out transgender patients and interferes with provider discretion and access to medically appropriate care. Another likely dispute is whether the bill improperly targets a specific patient population through the financing rules of the 340B program rather than through direct health policy.
Requiring certain 340B entities to report annually to the Kansas department of insurance on certain costs, savings and payments made under the federal 340B drug pricing program.